Linoa Holding AG

In 2004, Stefan Schwab established Linoa Holding AG to buy out Schwab-Feller AG. Linoa leverages the commercial success of Schwab-Feller to make long-term investments in high-tech and medtech companies with great potential. In doing so, Linoa plays its part in shaping the world of tomorrow. Linoa also invests in pet projects like KREANDO and AURUM, an innovative training concept with a focus on effectiveness, time efficiency and safety.

Linoa leaves nothing to chance when it comes to choosing which firms to invest in, which is why all potential candidates undergo a detailed and clearly structured evaluation. Linoa’s investment strategy zeroes in on B2B firms that provide niche markets with highly specialised products which are geared towards well-defined customer needs. Preference is given to companies in the challenging scale-up phase.

Here, Stefan Schwab can rely on support and input from a close-knit team of highly qualified experts, like: Prof. Dr. med. Klaus Neftel.

Stefan Schwab is a Swiss entrepreneur and investor

Stefan Schwab

Stefan Schwab, with his partner Klaus Neftel, goes beyond simply crafting a vision for the companies he invests in. He works hand in hand with their operational management teams to ensure that this vision becomes an integral part of an actionable strategy, and closely follows and assists the company during the implementation phase.
Prof. Dr. med. Klaus Neftel

Prof. Dr. med. Klaus Neftel

Klaus Neftel brings his medical and scientific expertise to bear at Linoa, and is largely responsible for shaping the company's medtech strategy. Between 1989 and 2000, Prof. Neftel was Head of Internal Medicine at the Ziegler Hospital in Bern. He subsequently founded Medtec AG, which created, among others, a nationwide ongoing training platform for medical professionals that combines eLearning modules with classroom-based teaching. Prof. Neftel is also the editor of the Swiss Medical Association journal 'Swiss Medical Forum'. His scientific research focuses on the effects of commonly used antibiotics on DNA/RNA replication, macrophage activation, and the immunological and toxicological features of drugs intolerance. Since 2002, Prof. Neftel has devoted his energies to the analysis of the biotech and medtech industries and emerging trends in these fields. In addition to his consultancy work for Linoa, he also works for the private bank Notenstein La Roche.